In a nutshell This study aimed to investigate the long-term safety and effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) versus obinutuzumab with chlorambucil (Leukeran) in patients with chronic lymphocytic leukemia (CLL) that have never received treatment (treatment-naive). This study concluded that the...
Read MoreLeukemia Posts on Medivizor
Evaluating the safety and effectiveness of optimized conformal total body irradiation in children with with blood cancer who received TCRαβ/CD19-depleted grafts
In a nutshell The study aimed to investigate optimized conformal (OC) total body irradiation (TBI) in pediatric patients with blood cancers who received further chemotherapy and allogeneic hematopoietic stem cell transplant (alloHSCT) with TCRαβ/CD19 depletion. This study concluded that OC-TBI is a...
Read MoreEvaluating antibody response rates of patients with chronic lymphocytic leukemia to a third dose of mRNA COVID-19 vaccine
In a nutshell This study aimed to investigate the antibody response to a third mRNA COVID-19 vaccine of patients with chronic lymphocytic leukemia (CLL) who had failed to achieve an antibody response after the standard two-dose vaccination regimen. This study concluded that approximately a quarter of patients responded to the third...
Read MoreEvaluating the safety and effectiveness of blinatumomab for the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia.
In a nutshell This study evaluated the safety and effectiveness of blinatumomab (Blincyto) for the treatment of children with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). The data showed that blinatumomab was safe and effective for these patients. Some background B-ALL is a type of cancer in which the body makes...
Read MoreWhat is the usefulness of measurable residual disease in patients with acute myeloid leukemia treated with venetoclax and azacitidine?
In a nutshell This study aimed to investigate the outcomes for acute myeloid leukemia (AML) patients treated with venetoclax (Venclexta) and azacitidine (Vidaza) who achieved complete remission (CR) and minimal measurable residual disease (MRD) after treatment. This study concluded that patients who achieved both CR and minimal...
Read MoreVacations for Adult Cancer Patients: Update
Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update. Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...
Read MoreEvaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL
In a nutshell The study aimed to investigate if allogeneic hematopoietic stem cell transplant (alloHSCT) was a suitable treatment strategy for patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) after chimeric antigen receptor (CAR) T-cell therapy. This study concluded that this was a suitable treatment...
Read MoreTreating chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab and high-dose methylprednisolone
In a nutshell This study aimed to investigate using rituximab (Rituxan) and high-dose methylprednisolone (HDMP; Medrol) as a treatment for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This study concluded that this treatment is a good option for elderly and frail patients and can work as a bridge to...
Read MoreClofarabine-fludarabine-busulfan conditioning before hematopoietic stem cell therapy in children with acute leukemia
In a nutshell This study aimed to investigate the combination of clofarabine (Clolar)-fludarabine (Fludara)-busulfan (Busulfex) as a conditioning regime in hematopoietic stem cell transplant (HSCT) for children with acute leukemia. This study concluded that this combination is safe and effective in these patients. Some...
Read MoreUpdated NCCN guidelines for acute lymphoblastic leukemia.
In a nutshell These guidelines aimed to update treatment options for patients with Philadelphia chromosome-positive (Ph+) and negative (Ph-) acute lymphoblastic leukemia (ALL). Some background Acute lymphoblastic leukemia (ALL) represents 75% to 80% of acute leukemia among children and so is the most common form of childhood leukemia. It represents...
Read MoreInvestigating minimal residual disease and long-term outcomes in patients with chronic lymphocytic leukemia who have been treated with venetoclax-obinutuzumab
In a nutshell This study aimed to investigate minimal residual disease (MRD) and long-term outcomes of patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (Venclexta) and obinutuzumab (Gazyva). This study concluded that this treatment leads to an effective MRD reduction and has...
Read MoreEvaluating long-term outcomes after low dose pegylated interferon-α combined with dasatinib in patients with chronic phase chronic myeloid leukemia
In a nutshell This study aimed to investigate the long-term safety and effectiveness of low-dose pegylated (PEG) interferon-α (IFN-α) combined with dasatinib in patients with chronic-phase (CP) chronic myeloid leukemia (CML). This study concluded that this treatment was safe and effective in the long-term in these...
Read More